PepsNMN (nicotinamide mononucleotide)
Early human evidenceNMN is a building block the body uses to make NAD+. A 10-week trial in postmenopausal women with prediabetes found better muscle insulin sensitivity with NMN than with placebo.
Also called: NMN, Nicotinamide mononucleotide
Featured study
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women ↗
Science (New York, N.Y.) · 2021 · PMID 33888596
- Who was studied
- Postmenopausal women with prediabetes who were overweight or obese.
- How
- 10-week randomized, double-blind, placebo-controlled trial using the hyperinsulinemic-euglycemic clamp, the reference method for measuring insulin sensitivity, plus muscle biopsies.
- What it found
- Insulin-stimulated glucose uptake and muscle insulin-signaling markers rose with NMN and did not change with placebo. Genes linked to muscle remodeling were also switched on.
- Limits
- This was one small, short trial in one narrow group. It did not show changes in blood sugar control, weight or health outcomes, and some authors disclosed NMN-related patents. A published scientific comment questioned how the results should be interpreted.
Safety & what remains unknown
No safety problems were highlighted in this short trial, but long-term human safety data are limited. NMN's status as a U.S. dietary supplement has been disputed by the FDA, so PepsRadar does not link to shops for it.
Talk to a clinician before starting a supplement, especially if you are pregnant, take prescription medicines or have a medical condition.
Where to find it
PepsRadar does not link to shops for this compound. See the safety section above.
← More in Energy & cellular aging
For research and education only. This page does not provide medical advice, diagnosis, or treatment, and is not a recommendation to use any product.